Wang Rosa, Lu Hui, Fernandez Gabriela, Krucien Nicolas, Huang Dong, Higashiyama Hiroshi, Du Juan, Ye Xin, Tervonen Tommi, Quaife Matthew
Daiichi Sankyo, Inc., Basking Ridge, NJ, United States.
Evidera, London, United Kingdom.
Prev Med Rep. 2025 Apr 25;54:103084. doi: 10.1016/j.pmedr.2025.103084. eCollection 2025 Jun.
Stroke prevention in patients with atrial fibrillation should be adapted to patient needs and preferences. This study quantifies patient preferences for key characteristics of atrial fibrillation stroke prevention treatments in China, Taiwan, and South Korea.
A discrete choice experiment (DCE) survey was developed based on a targeted literature review and discussions with clinical and methodological experts. The DCE included six attributes: risks of death, severe disabilities, mild or moderate disabilities, non-disabling events; intake with food; and dosing frequency. DCE data were analyzed using mixed multinomial logit models.
In January to March 2023, 307 participants completed the DCE in China ( = 155), Taiwan ( = 76), and South Korea (n = 76). Average time since atrial fibrillation diagnosis was 6.3 years. Participants preferred treatments with improved clinical outcomes, with reduced risk of death being their most important attribute. They valued a 1 % reduction in severe disability risk the same as a 0.36 % death risk reduction, a 1 % reduction in mild or moderate disability risk the same as a 0.25 % death risk reduction, and a 1 % reduction in non-disabling event risk the same as a 0.18 % death risk reduction. Participant preferences on intake with food and dosing frequency were more heterogeneous than for clinical outcomes.
Patients with atrial fibrillation were willing to accept an increased risk of non-disabling events in exchange for a reduced risk of death but had diverse preferences for treatment administration characteristics. These findings can inform patient-centered treatment strategies that consider the relative importance of treatment attributes in clinical decision-making.
心房颤动患者的卒中预防应根据患者的需求和偏好进行调整。本研究量化了中国、台湾地区和韩国患者对心房颤动卒中预防治疗关键特征的偏好。
基于有针对性的文献综述以及与临床和方法学专家的讨论,开展了一项离散选择实验(DCE)调查。DCE包括六个属性:死亡风险、严重残疾、轻度或中度残疾、非致残事件;与食物同服;以及给药频率。使用混合多项logit模型分析DCE数据。
2023年1月至3月,307名参与者在中国(n = 155)、台湾地区(n = 76)和韩国(n = 76)完成了DCE。自心房颤动诊断以来的平均时间为6.3年。参与者更喜欢临床结局改善的治疗方法,降低死亡风险是他们最重要的属性。他们认为严重残疾风险降低1%与死亡风险降低0.36%相当,轻度或中度残疾风险降低1%与死亡风险降低0.25%相当,非致残事件风险降低1%与死亡风险降低0.18%相当。参与者对与食物同服和给药频率的偏好比临床结局更为异质。
心房颤动患者愿意接受非致残事件风险增加以换取死亡风险降低,但对治疗给药特征有不同偏好。这些发现可为以患者为中心的治疗策略提供参考,这些策略在临床决策中考虑了治疗属性的相对重要性。